Cardiff Oncology Inc
CRDF
查看详细走势图
1.610USD
+0.010+0.63%
交易中 （美东）报价延迟15分钟
108.02M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.63%
5天
-8.00%
1月
-49.21%
6月
-32.64%
今年开始到现在
-42.70%
1年
-64.22%
查看详细走势图
TradingKey Cardiff Oncology Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Cardiff Oncology Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名129/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价10.38。中期看，股价处于下降通道。近一个月，市场表现非常差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cardiff Oncology Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Cardiff Oncology Inc亮点
亮点风险
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
业绩高增长
公司营业收入稳步增长，连续3年增长76.94%
业绩增长期
公司处于发展阶段，最新年度总收入683.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入683.00K美元
估值合理
公司最新PE估值-2.02，处于3年历史合理位
机构减仓
最新机构持股23.08M股，环比减少0.00%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值5.84K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.06
分析师目标
根据
9
位分析师
买入
评级
10.375
目标均价
+548.44%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cardiff Oncology Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cardiff Oncology Inc简介
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
公司代码CRDF
公司Cardiff Oncology Inc
CEOErlander (Mark)
网址https://cardiffoncology.com/
相关品种
